Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continu ...

Bio-Rad (BIO) delivered earnings and revenue surprises of -31.77% and +1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

From cell biology to ecosystems, virtual labs are making science more interactive, accessible, and engaging than ever. Students can experiment, make mistakes, and learn in safe, flexible environments.

TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from ...

From groundbreaking DNA experiments to running PCR and gel electrophoresis in the lab, molecular biology education now blends historic discoveries with modern practice. Students gain skills through a ...